

Vaccines Against *Mycobacterium tuberculosis*: An Overview from Preclinical Animal Studies to the Clinic

Rhea N. Coler, Susan L. Baldwin, and Steven G. Reed
*Infectious Disease Research Institute (IDRI) Seattle,
USA*

1. Introduction

More than a decade ago the World Health Organization (WHO) declared tuberculosis (TB) a global emergency and called on the biomedical community to strengthen its efforts to combat this scourge. The WHO predicts that by 2020 almost one billion people will be infected, with 35 million dying from the disease if research for new approaches to the management of this disease is unsuccessful (1). Designing a better TB vaccine is a high priority research goal. This chapter will review the various strategies currently being used to prevent and treat TB. In spite of the numerous new vaccine candidates in clinical trials, and several others in the preclinical pipeline, no clear TB vaccine development strategy has emerged.




Fig. 1. Estimated TB incidence rates, by country, 2009 [[http://para410.com/biophysical\(2\)](http://para410.com/biophysical(2))].

Despite TB control programs, *Mycobacterium tuberculosis* (Mtb), a facultative bacterial pathogen, remains the most common cause of infectious disease-related mortality

worldwide. Nearly 2 billion people are estimated to be infected with TB. Figure 1 shows the global distribution of TB incidence rates in 2009. Nearly 10 million individuals developed active TB globally (range, 8.9 million–9.9 million; equivalent to 137 cases per 100,000 population), and 1.7 million HIV-negative and HIV-positive people died of TB or related complications (3). TB has now become the leading cause of death in HIV-positive patients and is thought to accelerate the progression of HIV disease (4). Worldwide, 1 in every 3 people is infected with Mtb (5) and may harbor *Mycobacterium* bacilli in their lungs, thus serving as an important reservoir (6). Most of these TB cases occur in India, China, Africa and Indonesia, where 1 in every 8 deaths is a result of TB (7).

Resistance to single anti-mycobacterial agents has long been recognized. Fortunately, the standardized use of multiple agents to treat active disease and the common use of directly observed therapy (DOT), where a health care worker ensures chemotherapy regimens are taken by patients as recommended, have made a significant impact on mitigating treatment regimens and mortality. Unfortunately, the evolution of drug resistance has led to the emergence of TB strains resistant to multiple agents, including those medications used as standard first-line therapies. Fifty million of those infected have multi-drug resistant (MDR)-TB, a disease caused by Mtb strains that are resistant to both isoniazid and rifampicin with or without resistance to other first-line drugs. The incidence of MDR-TB is rapidly growing, and the total number of estimated cases has steadily increased. The estimated global incidence of MDR-TB was 275,000 cases in 2000 and 440,000 cases in 2008 (8, 9). Nevertheless, the true prevalence of MDR-TB is likely under-recognized as many developing countries endemic for TB lack appropriate lab facilities, diagnostic resources and epidemiological capabilities (10). MDR strains do not appear to cause disease more readily than their drug sensitive counterparts, but HIV-positive individuals infected with MDR-TB have higher mortality rates, perhaps because HIV infection causes a malabsorption of TB drugs. This, and the fact that MDR-TB can require 24 months or more of drug therapy compared to 6-9 months for drug sensitive strains, can lead to acquired drug resistance and up to a 300-fold increase in drug costs (11).

Since the discovery of MDR-TB in the 1990s, the resistance pattern of TB has continued to evolve, and isolates resistant to both first- and second-line agents, termed extensively drug-resistant TB (XDR-TB), have been identified. Like MDR-TB, XDR-TB has been identified worldwide and now represents 2% of all cases of culture-positive TB (10).

Societal costs associated with MDR-TB are higher than for drug-susceptible TB due to longer hospitalization, longer treatment with more expensive and toxic medications, greater productivity losses, and higher rates of treatment failure and mortality. There have been recent reports of greater than 20% and 80% mortality attributable to MDR-TB and XDR-TB, respectively, with less than 60% of disease free MDR-TB patients after a mean drug treatment period of four years (12). In the U.S., where there are on average 300 newly reported cases of MDR-TB annually, this disease is very expensive to treat and current estimates suggest it is more than ten times as expensive as drug-sensitive infections (13-15).

2. BCG...then and now...

The bacille Calmette-Guérin (BCG) vaccine, derived from an attenuated strain of *Mycobacterium bovis*, has been used to vaccinate over 3 billion people throughout the world

for more than 80 years since 1928. BCG lacks the genomic 'Region of Difference' (RD1) which encodes the ESX-1 secretion system, including the immunodominant 6-kDa Mtb antigen ESAT-6, included in the Hybrid 1 (ESAT-6/Ag85) vaccine (described in more detail in a later section of this chapter) and in IFN- γ release assays (IGRA's) used to diagnose Mtb (16, 17). The overriding dogma is that BCG protects against primary childhood TB, but its role in consistently protecting against adult pulmonary disease is minimal (18). Indeed, the efficacy of BCG in several field trials has been variable (19). The suggested reasons for the variability observed include differences in the BCG strains - resulting from inconsistent laboratory culture conditions which caused gene deletions or attenuated organisms (20), poor handling of the vaccine, doses and vaccination schedules in the various field trials (21), interference from environmental mycobacteria (22-24), and poor nutrition or genetic variability in the populations immunized (25, 26). Several analyses have identified genetic changes within some BCG substrains such as in the *phoP-phoR* system that has occurred along the way since BCG Pasteur was first derived.

Except in cases where infants are HIV-seropositive, BCG is considered safe. This has led to development of other vaccines that either enhance the immune responses resulting from BCG immunization, for example by insertion of specific genes present in virulent *M. tuberculosis* but which have been lost in the avirulent BCG vaccine - the recombinant forms of BCG (rBCG) - or, more broadly, are capable of boosting the effects of BCG. Recent studies have demonstrated that the new rBCG vaccines are more immunogenic, inducing effector and memory T cells, however one potential concern is that many of these rBCGs encode antigens such as Ag85A, CFP-10 etc. that are immunodominant. Recent data suggest that these antigens are highly conserved and are used by the bacteria as a ploy to cause damage in the lungs resulting in escape of the mycobacteria bacilli and increased transmission. It is important to demonstrate whether the new rBCGs can protect against clinical strains. Furthermore, because BCG is designed to be administered only once, none of the rBCG strategies are likely to yield a successful vaccine superior to what we have now.

Over the last 10 years more than 170 TB vaccine candidates have been tested in mouse, guinea pig or non-human primate models of TB (27-31). These include: (i) subunit vaccines consisting of mycobacterial preparations (32-34), culture filtrates (CF) or secreted molecules (35-39), proteins (40-53), lipoglycoproteins (54), and glycolipids (55-57); (ii) DNA vaccines (58-72); (iii) live, attenuated, nonpathogenic/auxotrophic or recombinant bacteria (73-81); and (iv) attenuated, nonmycobacterial vectors such as *Salmonella* or *Vaccinia* virus (77, 82-87). In addition, attempts at improving BCG by administering lower doses (88-90), oral delivery (91), and prime/boost protocols are being explored (59, 85, 92-94). Currently, several candidate vaccines are being prepared for testing primarily as pre-exposure vaccines in humans (27, 95, 96).

Vaccine approaches currently in clinical trials also include altered forms of BCG to increase the effectiveness of the treatment. One of the vaccines, rBCG30, is an engineered form of BCG (rBCG) that over expresses Ag85B (97). It has shown much greater efficacy than the parental Tice BCG vaccine, perhaps due to loss of virulence in the current BCG vaccines, and was shown to increase Ag85B-specific T cell proliferation and IFN- γ responses in humans (97). Another rBCG in human clinical trials is a rBCG that is a urease-deficient mutant that expresses the lysteriolysin O gene from *Listeria monocytogenes* (98). Using this approach the vaccine increases phagosomal acidification in the absence of the ureC enzyme,

while expressing the lysteriolysin protein, Hly, which requires an acidic pH within the phagosome in order to damage/perforate the phagosomal membrane. This process allows the release of antigen into the cytoplasm and induces macrophage apoptosis, leading to enhanced CD8⁺ T cell presentation through a cross-priming strategy. Other whole virus vaccine approaches have seen some success against TB. One, based on a recombinant modified vaccinia virus Ankara (MVA) vaccine which expresses the Mtb protein Ag85A, is currently in clinical trials (99). However, the complex nature of TB infections may very well require multiple weapons in our armamentarium. These may include not only the use of multiple Mtb antigens but also vaccines based on other adjuvant and delivery platforms.

A post-exposure vaccine, to be used in healthy individuals infected with Mtb or those recently exposed to MDR-TB, could also reduce the probability of going on to develop TB disease. It could work by limiting bacteria that cause TB or MDR-TB, that are residing in a dormant state, by preventing reactivation and/or by reducing the chance of reinfection by exogenous Mtb. Finally, a therapeutic vaccine could function alone, or alongside antibiotic regimens, for individuals with active TB disease and could potentially shorten the treatment period.

3. Immune responses required for development of a successful TB vaccine...

Advances in our knowledge of resistance to Mtb have emerged since the pioneering work of Mackaness (1960's, 1070's) who demonstrated a dependence on cellular immunity against mycobacterial infection (100, 101). Another key advancement to the development of vaccines against Mtb was made by Orme and Collins (1980's), who were the first to show that transfer of immunity against Mtb could be achieved with antigen-specific CD4 and CD8 T cells, and that metabolically active mycobacteria secreted key immunologically relevant antigens (102-106). A major new idea in the mid-1980's, that has shaped the development of vaccines against many different pathogens, was that of Mosmann with the discovery that there were two types of helper CD4 T cells: Thelper 1 and Thelper 2 cells, that secrete either IFN γ or IL-4 respectively (among other cytokines) (107). More recently, Sallusto et al. have defined memory T cell subsets which can be functionally separated based on their surface receptors, which further advance testing the capability of vaccine induction of long-lived immune responses (108, 109). Although our understanding of an effective immune response against Mtb is far from complete, some fundamentals have been identified, resulting in a number of TB vaccines that are now being tested in humans. Several of these advances in our knowledge of the host's resistance to Mtb are discussed in the remainder of this chapter.

Mycobacteria bacilli usually enter the host through aerosol droplets of 1-3 μ M inhaled to the lung alveoli. Some bacilli remain in the lungs and evade adaptive immunity to persist in the lungs, often for the lifetime of the host, and some are transported to draining lymph nodes where dendritic cells (DC) prime T lymphocytes. Mtb undergoes an initial period of uninhibited growth within non-activated host macrophages (110). Cell mediated immunity (CMI) characterized by the expansion of antigen-specific T-lymphocytes that attract monocytes/macrophages to inhibit bacillary growth through the production of cytokines, plays a key role in the control of TB. Persistence of Mtb inside of mononuclear phagocytes and DCs during all stages of infection can occur via many mechanisms including down-regulating major histocompatibility complex (MHC) class II expression or presentation

(111), neutralizing the phagosomal pH, interference with autophagy, and by inducing the production of immunosuppressive cytokines such as interleukin (IL)-10 and tumor growth factor beta (TGF- β)(112-115). Mtb can also inhibit apoptosis through prostaglandin production (116) and can invade the cytosolic compartment (117). Recent data also showed that of the large number of CD4⁺ effector T cells recruited to the lungs of infected mice, few are stimulated to produce IFN- γ (118).

The hallmark of CMI to Mtb infection is the formation of solid granulomas from aggregates of mononuclear phagocytes and polymorphonuclear granulocytes in the lung with a center of infected macrophages surrounded by a marginal zone of lymphocytes (119, 120). The protective role of granulomas is confinement of bacilli in a space that is lacking in vascularity and alveolar air, preventing both replication and dissemination to other sites. Granulomas also serve as sites for priming of CD4⁺ and CD8⁺ T cells as well as germinal center B cells. Primed T cells are reported to be polyfunctional, secreting IFN- γ , TNF and IL-2 cytokines, and of the central memory lineage (T_{cm}) (121) (Figure 2). Studies in gene-deficient/knock out (KO) mice and through neutralization with antibodies, have demonstrated the importance of IFN- γ (122-131), CD4⁺, and CD8⁺ (132-141) T cells in the acquired immune response to Mtb.

CD4⁺ T cells traffic to the lung within 7-14 days following infection and produce IFN- γ (142, 143). Depletion of CD4⁺ T cells prior to Mtb infection leads to increased bacterial burden and shortened survival (138) and depletion of this subset in latently infected animals leads to rapid reactivation (144). In sublethally-irradiated mice, passive transfer of CD4⁺ T cells mediates reduced susceptibility to Mtb infection (145). In contrast, CD4⁻ and MHC Class II-deficient mice are extremely susceptible to Mtb. Finally, clinical conditions that impair CD4⁺ T cell immunity, such as HIV infection, dramatically increase the likelihood of developing active TB.

Mice deficient in IFN- γ , an effector cytokine which defines Th1-type CD4⁺ T cells, are highly susceptible to Mtb infection (127, 146). These mice fail to produce nitric oxide (NO) synthase (127) and develop a disseminated form of disease, characterized by irregular granulomas and necrotic areas. Patients in whom the gene for the IFN- γ receptor is mutated are prone to infection with atypical mycobacteria (147). Strong Th1-type, antigen-specific IFN- γ -secreting T cells are found in peripheral blood mononuclear cells (PBMC) from healthy individuals with latent TB infections (LTBI), but are diminished in individuals with pulmonary TB (148, 149). Recent results also indicate that CD4⁺ effector T cells are activated at suboptimal frequencies in tuberculosis, and that increasing effector T cell activation in the lungs by providing one or more epitope peptides may be a successful strategy for TB therapy (150).

The protective role of TNF in the immune response to Mtb was demonstrated in mice with defects in genes for TNF (151, 152). Its critical role for humans was also revealed by the occurrence of reactivation TB in rheumatoid arthritis patients who received long-term therapy with anti-TNF antibodies (153). Recently, both IL-23 and IL-17 were shown to be essential in the establishment of protective pulmonary CD4⁺ T cell responses, along with the concurrent expression of the chemokines CXCL9, CXCL10 and CXCL11 (154, 155).

Studies in mice and humans support an important role of CD8⁺ T cells in TB immunity, particularly during LTBI. Adoptive transfer or *in vivo* depletion of CD8⁺ cells demonstrated

that CD8⁺ cells could confer protection against subsequent Mtb challenge, although the effects were less pronounced than those seen with CD4⁺ T cells (156-158). Mtb can egress into the cytosolic compartment of infected DCs resulting in direct loading of MHC class I (117). Cross-priming, which involves apoptosis of macrophages infected with Mtb, uptake of vesicles carrying Mtb antigens by nearby DC, and antigen presentation of the vesicular antigens by MHC I to CD8 is an additional mechanism by which CD8⁺ T cells are stimulated (159). Mice deficient in class I processing and presentation, including deficiencies in β 2 microglobulin (160, 161), TAP1 (162), CD8, or Class Ia (K^b -/-/ D^b -/-) (163), are all more susceptible to Mtb infection than wild-type animals. In humans, Mtb-specific CD8⁺ T cells have been identified in Mtb-infected individuals and include CD8⁺ T cells that are classically (164-169), non-classically (170, 171), and CD1 restricted (172, 173).




Fig. 2. The Cellular Host Response to TB. After infection of the host lung, macrophages and DCs infected with Mtb stimulate CD4⁺ and CD8⁺ T cells. CD4⁺ T cells are polarized into Th1 and Th17 effector cells or memory T cells secreting multiple cytokines including IFN- γ , TNF and IL-2. CD8⁺ memory T cells may be cytolytic and may secrete TNF and IFN- γ .

Infection with Mtb induces robust T cell responses yet adaptive immunity fails to eradicate *M. tuberculosis*. Mechanisms for the limited efficacy of the adaptive immune response in

tuberculosis are hypothesized to fall into two categories: either the T cell effector functions are not effective because of failed or inappropriate responses induced by the infected cells; or the T cells recruited to the site of infection do not optimally perform the effector functions required for immune clearance. The ability of *M. tuberculosis* to resist and inhibit the TNF and IFN- γ -induced microbicidal responses of the phagocytic cells it infects is one immune evasion strategy in vivo. Another is that only a small fraction of the CD4 + effector T cells in the lungs is activated to synthesize IFN- γ . Identification of the elements of this host-pathogen interaction may lead to the development of therapies that target antigen gene suppression and inhibition of antigen presentation and provide a novel strategy for overcoming bacterial persistence in vivo, leading to better outcomes in Mtb infected individuals.

4. Designing a sub-unit vaccine from start to finish...

This section highlights the development of a new subunit vaccine, ID93/GLA-SE, and briefly discusses the other human TB vaccine candidates in the pipeline (see Table I).

Preclinical studies with a new TB subunit vaccine, ID93/GLA-SE, have been conducted and this vaccine is ready for testing in Phase I human clinical studies. This vaccine now joins 14 others, which are currently being tested in humans (Table I). The selection of the proteins for ID93 involved the generation of an Mtb protein library based on H37Rv proteins that were within the known immunogenic EsX and PE/PPE classes, between 6 and 70 kDa and with low homology with the human genome (less than 30%) (174). A comprehensive analysis was then performed on over 100 potential candidate antigens selected based on genome mining and expression as recombinant proteins. These candidate antigens were then down-selected based on IFN- γ production from human PBMCs in patients that were PPD(+) and which were non-responsive in PPD(-) patient samples. In combination with the TLR9 agonist, CpG ODN 1826, the vaccine candidates were then tested for efficacy in the C57BL/6 mouse aerosol model of Mtb infection. The ID93 fusion protein consists of four selected Mtb proteins: Rv3619, Rv1813, Rv3620, and Rv2608 (the cumulative molecular weights of each individual protein define the "93" in ID93). Three of the proteins are associated with Mtb virulence (Rv2608, Rv3619, and Rv3620) and one with latency (Rv1813). Rv2608 is a member of the PE/PPE family, Rv3619 and 3620 are in the EsX family of proteins and Rv1813 is expressed under hypoxic conditions (174). Similar to other fusion proteins, including Mtb72F, Ag85B-ESAT6, Ag85B-TB10 and H56, the fusion of more than one Mtb antigen leads to increased vaccine efficacy. Another similarity of these subunit vaccines is the need for an adjuvant to elicit maximum efficacy.

The adjuvant selected for use with the ID93 vaccine is a synthetic toll-like receptor (TLR4) agonist called glucopyranosyl lipid adjuvant (or GLA). This molecule has been extensively characterized in many biological systems, including mice, guinea pigs, ferrets (unpublished results), hamsters, non-human primates (NHPs) and humans (52, 175, 176). Early on, the Mtb72F subunit vaccine, in Phase II human clinical trials, included AS02A as its adjuvant. AS02A consists of a biological TLR4 agonist called monophosphoryl lipid A (MPL), derived from *Salmonella minnesota* mixed with QS21 and an oil-in-water formulation (177).

Other TB vaccine candidates currently in clinical trials include four different categories of vaccines: a) recombinant protein vaccines; b) recombinant live vaccines; c) viral vectored

vaccines; and d) whole cell, inactivated or disrupted mycobacterial vaccines (Table 1). The recombinant subunit vaccines will be briefly described below.

	Protein/Vaccine	Adjuvant
Recombinant Proteins		
M72	fusion protein of Mtb32 and Mtb39 (72kDa)	AS02A: MPL and QS21
Hybrid 1	fusion protein of Ag85B and ESAT-6	IC31 (Intercell): ss oligodeoxynucleotide and peptide (KLKL5KLK)
Hybrid 1	fusion protein of Ag85B and ESAT-6	CAF01: cationic liposomes
HyVac4: AERAS-404	fusion protein of Ag85B and TB10.4	IC31 (Intercell): ss oligodeoxynucleotide and peptide (KLKL5KLK)
Recombinant Live Vaccines		
VPM1002: rBCG(delta)ureC:Hly	urease deficient; expresses listeriolysin (Hly) from <i>L. monocytogenes</i>	NA
rBCG30 (Tice strain): AERAS-422	rBCG30; overexpresses Ag85B	NA
rBCG (AFRO-1 strain): AERAS-422	rBCG30; overexpresses Ag85A, Ag85B and Rv3407 and expresses perfringolysin O	NA
Viral Vectored Vaccines		
MVA85A: AERAS-485	MVA (Modified vaccinia virus Ankara) expressing Ag85A	NA
Crucell Ad35: AERAS-402	Ad35 (non-replicating Adenovirus 35) expressing Ag85A, Ag85B and TB10.4	NA
Ad5Sg85A	Ad5 (non-replicating Adenovirus 5) expressing Ag85A	NA
Whole Cell Inactivated or Disrupted Vaccines		
<i>M. vaccae</i>	Inactivated whole cell mycobacteria	NA
Mw [<i>M. indicus pranii</i> (MIP)]	Whole cell saprophytic mycobacteria	NA
RUTI	Fragmented <i>M. tuberculosis</i> cells	NA
<i>M. smegmatis</i>	Whole cell extract	NA

Table 1. TB vaccines in human clinical trials (178), [TB vaccine candidates-2010; [www.stoptb.org/wg/new_vaccines\(2\)](http://www.stoptb.org/wg/new_vaccines(2))].

The M72 (Mtb72F) + AS01 (or AS02A) vaccine was originally developed by Corixa and the Infectious Disease Research Institute (Seattle, WA) and clinical trials are currently being sponsored by GlaxoSmithKline (GSK) and Aeras. This vaccine is a fusion of tandemly linked proteins, Mtb32(C), Mtb39, and Mtb32(N) which showed efficacy in mice, guinea pigs, and NHPs (179-181) and is currently being evaluated in humans. This vaccine includes an AS01 adjuvant (GSK), which comprises the TLR4 agonist, monophosphoryl lipid A (MPL), QS21 and liposomes. In the first phase I clinical trial, Mtb72F combined with the AS02A adjuvant, which includes MPL, QS21, and an oil-in-water emulsion, the vaccine was locally reactogenic but the adverse events were mostly mild and transient and thus had an acceptable tolerability in humans (177). Immunologically, three doses of the Mtb72F/AS02A vaccine (given at 0, 1 and 2 months) induces both humoral and cellular responses in healthy PPD-negative adults (18-40 years of age); IL-2 and IFN- γ is elicited in PBMCs by ELISPOT and increased antigen-specific CD4+ T cells expressing CD40L, IL-2, TNF- α and IFN- γ by intracellular cytokine staining (ICS) are also induced.

The Hybrid-1 vaccine developed by the Statens Serum Institute, includes a fusion of the Mtb proteins antigen 85B and ESAT6. This vaccine, Hybrid 1, which is being evaluated in human clinical trials, is adjuvanted with either the Intercell adjuvant system, IC31 or with a liposomal adjuvant CAF01. CAF01 adjuvant is considered a cationic liposome, and is formulated with quaternary ammonium lipid N, N'-dimethyl-N,N'-dioctadecylammonium (DDA) plus a synthetic mycobacterial cord factor, α,α' -trehalose 6,6'-dibeheneate (TDB) (182-184). The IC31 adjuvant signals through TLR9, and contains the following KLK polypeptide KLKL₅KLK-COOH and a non-CpG oligonucleotide ODN1a, consisting of a phosphodiester backbone ODN, 5'-ICI CIC ICI CIC ICI CIC ICI CIC IC-3' (185). Both adjuvant systems, CAF01 and IC31, elicit strong Th1 inducing activities and protection in animal models of tuberculosis when combined with the Ag85B-ESAT6 fusion (185-189).

Another subunit vaccine in development by the same group that developed the Hybrid-1 vaccine is the H56 vaccine which includes a fusion of Hybrid 1 and a latency-associated protein, Rv2660c, which is activated during hypoxic conditions (50). The H56 vaccine, formulated in CAF01, shows a 10-fold reduction in lung bacterial load in the mouse model in a head-to-head comparison with their precursor subunit vaccine, the Hybrid 1 vaccine, containing only Ag85B and ESAT6. In addition, the authors demonstrate that the H56 vaccine is capable of protecting against reactivation when tested after Mtb exposure in a modified Cornell mouse model. HyVac4/AERAS-404 combined with IC31 is also in clinical trials, and includes a fusion of the Mtb antigens Ag85B and TB10.4. Replacement of the ESAT-6 protein with TB10.4 in this vaccine, conserves the use of ESAT-6 for diagnostic purposes (16, 190). This vaccine induces polyfunctional CD4 T cells, which express IFN- γ , TNF- α and IL-2, correlating with protective efficacy in the mouse model against Mtb (191) and guinea pig model using a BCG prime/subunit boost strategy (192).

5. Conclusion

Today, an ambitious portfolio of novel vaccines, drug regimens, and diagnostic tools for TB is being supported by various research funding agencies. Mathematical modeling of TB to evaluate the potential benefits of novel interventions under development and those not yet in the portfolio suggest that: neonatal vaccination with an effective portfolio vaccine would

decrease TB incidence by 39% to 52% by 2050, while drug regimens that shorten treatment duration and are efficacious against drug-resistant strains could reduce incidence by 10-27%. Clearly, TB elimination will require one or more effective vaccines. Importantly, new vaccines should have the potential to be effective against clinical strains representing all the major geographical regions.

6. References

- [1] <http://www.who.int/mediacentre/factsheets/fs104/en>. WHO Fact Sheet No. 104, November 2010.
- [2] <http://www.stoptb.org/>
- [3] WHO. Global tuberculosis control. WHO Report 2010. Geneva, World Health Organization.
- [4] Nunn P, Reid A, De Cock KM. Tuberculosis and HIV infection: the global setting. *J Infect Dis.* 2007;196 Suppl 1:S5-14.
- [5] Sudre P, ten Dam G, Kochi A. Tuberculosis: a global overview of the situation today. *BullWorld Health Organ.* 1992;70(2):149-59.
- [6] Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. 1082. *Tubercle*1991. p. 1-16.
- [7] Cegielski JP, Chin DP, Espinal MA, Frieden TR, Rodriguez Cruz R, Talbot EA, et al. The global tuberculosis situation. Progress and problems in the 20th century, prospects for the 21st century. *Infect Dis Clin North Am.* 2002;16(1):1-58.
- [8] Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug-resistant tuberculosis. *Journal of Infectious Diseases.* 2002;185(8):1197-202.
- [9] WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva; 2010 Contract No.: Document Number | .
- [10] Zignol M, Wright A, Jaramillo E, Nunn P, Raviglione MC. Patients with previously treated tuberculosis no longer neglected. *Clin Infect Dis.* 2007;44(1):61-4.
- [11] Bock NN, Jensen PA, Miller B, Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. *J Infect Dis.* 2007;196 Suppl 1:S108-13.
- [12] Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR, Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. *New England Journal of Medicine.* 1993;328(8):527-32.
- [13] Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. *Chest.* 1997;112(1):63-70.
- [14] Wilton P, Smith RD, Coast J, Millar M, Karcher A. Directly observed treatment for multidrug-resistant tuberculosis: an economic evaluation in the United States of America and South Africa. *Int J Tuberc Lung Dis.* 2001;5(12):1137-42.
- [15] Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. *Nature reviews.* 2009;7(1):81-7.
- [16] Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, Conlon CP, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-

- specific T cells. American journal of respiratory and critical care medicine. 2001;163(4):824-8.
- [17] Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. American journal of respiratory and critical care medicine. 2004;170(1):59-64.
- [18] Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995;346(8986):1339-45.
- [19] Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of GCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. 1088. JAMA. 1994;271:698-702.
- [20] Behr MA. BCG--different strains, different vaccines? The Lancet infectious diseases. 2002;2(2):86-92.
- [21] Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray [see comments] 7. Science. 1999;284(5419):1520-3.
- [22] Brandt L, Feino CJ, Weinreich OA, Chilima B, Hirsch P, Appelberg R, et al. Failure of the *Mycobacterium bovis* BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infection and Immunity. 2002;70(2):672-8.
- [23] Palmer DR, Krzych U. Cellular and molecular requirements for the recall of IL-4-producing memory CD4(+)CD45RO(+)CD27(-) T cells during protection induced by attenuated *Plasmodium falciparum* sporozoites. Eur J Immunol. 2002;32(3):652-61.
- [24] Rook GA, Bahr GM, Stanford JL. The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCG 2084. Tubercle. 1981;62(1):63-8.
- [25] Fine PE. BCG: the challenge continues. Scand J Infect Dis. 2001;33(4):243-5.
- [26] Liu J, Tran V, Leung AS, Alexander DC, Zhu B. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Human vaccines. 2009;5(2):70-8.
- [27] Ginsberg AM. What's new in tuberculosis vaccines? Bull World Health Organ. 2002;80(6):483-8.
- [28] Orme IM. Prospects for new vaccines against tuberculosis 207. Trends Microbiol. 1995;3(10):401-4.
- [29] Orme IM. Progress in the development of new vaccines against tuberculosis 889. Int J Tuberc Lung Dis. 1997;1(2):95-100.
- [30] Orme IM. The search for new vaccines against tuberculosis. Journal of Leukocyte Biology. 2001;70(1):1-10.
- [31] Orme IM, Belisle JT. TB vaccine development: after the flood 825. Trends Microbiol. 1999;7(10):394-5.
- [32] Brehmer W, Anacker RL, Ribi E. Immunogenicity of cell walls from various mycobacteria against airborne tuberculosis in mice 772. Journal of Bacteriology. 1968;95(6):2000-4.

- [33] Chugh IB, Kansal R, Vinayak VK, Khuller GK. Protective efficacy of different cell-wall fractions of Mycobacterium tuberculosis 329. *Folia Microbiol(Praha)*. 1992;37(6):407-12.
- [34] Pal DP, Shrinivas. Role of cellwall vaccine in prophylaxis of tuberculosis 564. *Indian Journal of Medical Research*. 1977;65(3):340-5.
- [35] Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. *Infection and Immunity*. 1994;62(6):2536-44.
- [36] Boesen H, Jensen BN, Wilcke T, Andersen P. Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis. *Infection and Immunity*. 1995;63(4):1491-7.
- [37] Haslov K, Andersen A, Nagai S, Gottschau A, Sorensen T, Andersen P. Guinea pig cellular immune responses to proteins secreted by Mycobacterium tuberculosis 1286. *Infection and Immunity*. 1995;63(3):804-10.
- [38] Horwitz MA, Lee BW, Dillon BJ, Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. *ProcNatlAcadSciUSA*. 1995;92(5):1530-4.
- [39] Hubbard RD, Flory CM, Collins FM. Immunization of mice with mycobacterial culture filtrate proteins 1838. *Clinical and Experimental Immunology*. 1992;87(1):94-8.
- [40] Alderson MR, Bement T, Day CH, Zhu L, Molesh D, Skeiky YA, et al. Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells. *J Exp Med*. 2000;191(3):551-60.
- [41] Andersen AB, Hansen EB. Structure and mapping of antigenic domains of protein antigen b, a 38,000-molecular-weight protein of Mycobacterium tuberculosis 2152. *Infection and Immunity*. 1989;57(8):2481-8.
- [42] Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis 2383. *Infection and Immunity*. 2000;68(2):791-5.
- [43] Coler RN, Campos-Neto A, Owendale P, Day FH, Fling SP, Zhu L, et al. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. *J Immunol*. 2001;166(10):6227-35.
- [44] Collins HL, Kaufmann SH. Prospects for better tuberculosis vaccines. *Lancet InfectDis*. 2001;1(1):21-8.
- [45] Dillon DC, Alderson MR, Day CH, Lewinsohn DM, Coler R, Bement T, et al. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. *Infect Immun*. 1999;67(6):2941-50.
- [46] Skeiky YA, Lodes MJ, Guderian JA, Mohamath R, Bement T, Alderson MR, et al. Cloning, Expression, and Immunological Evaluation of Two Putative Secreted Serine Protease Antigens of Mycobacterium tuberculosis 1. *Infection and Immunity*. 1999;67(8):3998-4007.
- [47] Skeiky YA, Owendale PJ, Jen S, Alderson MR, Dillon DC, Smith S, et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. *J Immunol*. 2000;165(12):7140-9.
- [48] Sorensen AL, Nagai S, Houen G, Andersen P, Andersen AB. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis 1285. *Infection and Immunity*. 1995;63(5):1710-7.

- [49] Weinrich OA, van Pinxteren LA, Meng OL, Birk RP, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. *Infection and Immunity*. 2001;69(5):2773-8.
- [50] Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. *Nat Med*. 2011.
- [51] Baldwin SL, Bertholet S, Kahn M, Zharkikh I, Ireton GC, Vedvick TS, et al. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. *Vaccine*. 2009;27(23):3063-71. PMID: 2743149.
- [52] Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant *Mycobacterium tuberculosis*. *Sci Transl Med*. 2010;2(53):53ra74.
- [53] Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. *Nature medicine*. 2011;17(2):189-94.
- [54] Vordermeier HM, Zhu X, Harris DP. Induction of CD8+ CTL recognizing mycobacterial peptides 138. *Scandinavian Journal of Immunology*. 1997;45(5):521-6.
- [55] Anacker RL, Matsumoto J, Ribic E, Smith RF, Yamamoto K. Enhancement of resistance of mice to tuberculosis by purified components of mycobacterial lipid fractions. *J Infect Dis*. 1973;127(4):357-64.
- [56] Mara M, Galliova J, Sir Z, Mohelska H, Pruchova J, Julak J. Biochemistry of BCG lipids and their role in antituberculous immunity and hypersensitivity. *J HygEpidemiolMicrobiolImmunol*. 1975;19(4):444-52.
- [57] Reggiardo Z, Shamsuddin AK. Granulomagenic activity of serologically active glycolipids from *Mycobacterium bovis* BCG 574. *Infection and Immunity*. 1976;14(6):1369-74.
- [58] D'Souza S, Rosseels V, Denis O, Tanghe A, De Smet N, Jurion F, et al. Improved tuberculosis DNA vaccines by formulation in cationic lipids. *Infection and Immunity*. 2002;70(7):3681-8.
- [59] Feng CG, Palendira U, Demangel C, Spratt JM, Malin AS, Britton WJ. Priming by DNA immunization augments protective efficacy of *Mycobacterium bovis* Bacille Calmette-Guerin against tuberculosis. *Infection and Immunity*. 2001;69(6):4174-6.
- [60] Huygen K. DNA vaccines: application to tuberculosis 36. *IntJTubercLung Dis*. 1998;2(12):971-8.
- [61] Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine 2456. *NatMed*. 1996;2(8):893-8.
- [62] Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of *Mycobacterium tuberculosis* 23. *Infection and Immunity*. 1999;67(4):1702-7.
- [63] Kamath AT, Hanke T, Briscoe H, Britton WJ. Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against mycobacterium tuberculosis [In Process Citation] 11. *Immunology*. 1999;96(4):511-6.
- [64] Lowrie DB, Silva CL, Colston MJ, Ragno S, Tascon RE. Protection against tuberculosis by a plasmid DNA vaccine. *Vaccine*. 1997;15(8):834-8.

- [65] Lowrie DB, Silva CL, Tascon RE. DNA vaccines against tuberculosis. *Immunology and Cell Biology*. 1997;75(6):591-4.
- [66] Lozes E, Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, et al. Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. *Vaccine*. 1997;15(8):830-3.
- [67] Silva CL, Bonato VL, Lima VM. DNA encoding individual mycobacterial antigens protects mice against tuberculosis. *BrazJ MedBiolRes*. 1999;32(2):231-4.
- [68] Tanghe A, Content J, Van Vooren JP, Portaels F, Huygen K. Protective efficacy of a DNA vaccine encoding antigen 85A from *Mycobacterium bovis* BCG against Buruli ulcer. *Infection and Immunity*. 2001;69(9):5403-11.
- [69] Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. *NatMed*. 1996;2(8):888-92.
- [70] Ulmer JB, Liu MA, Montgomery DL, Yawman AM, Deck RR, DeWitt CM, et al. Expression and immunogenicity of *Mycobacterium tuberculosis* antigen 85 by DNA vaccination 130. *Vaccine*. 1997;15(8):792-4.
- [71] Ulmer JB, Montgomery DL, Tang A, Zhu L, Deck RR, DeWitt C, et al. DNA vaccines against tuberculosis 30. *NovartisFoundSymp*. 1998;217:239-46.
- [72] Velaz-Faircloth M, Cobb AJ, Horstman AL, Henry SC, Frothingham R. Protection against *Mycobacterium avium* by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent protein 845. *Infection and Immunity*. 1999;67(8):4243-50.
- [73] Bahr GM, Shaaban MA, Gabriel M, al Shimali B, Siddiqui Z, Chugh TD, et al. Improved immunotherapy for pulmonary tuberculosis with *Mycobacterium vaccae*. *Tubercle*. 1990;71(4):259-66.
- [74] Chambers MA, Williams A, Gavier-Widen D, Whelan A, Hall G, Marsh PD, et al. Identification of a mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against *M. bovis* and hematogenous spread of mycobacterium tuberculosis without sensitization to tuberculin [In Process Citation] 2403. *Infection and Immunity*. 2000;68(12):7094-9.
- [75] Collins DM, Wilson T, Campbell S, Buddle BM, Wards BJ, Hotter G, et al. Production of avirulent mutants of *Mycobacterium bovis* with vaccine properties by the use of illegitimate recombination and screening of stationary-phase cultures. *Microbiology*. 2002;148(Pt 10):3019-27.
- [76] Dhar N, Rao V, Tyagi AK. Recombinant BCG approach for development of vaccines: cloning and expression of immunodominant antigens of *M. tuberculosis* [In Process Citation]. *FEMS Microbiology Letters*. 2000;190(2):309-16.
- [77] Hess J, Kaufmann SH. Development of live recombinant vaccine candidates against tuberculosis. *ScandJ InfectDis*. 2001;33(10):723-4.
- [78] Hondalus MK, Bardarov S, Russell R, Chan J, Jacobs WR, Jr., Bloom BR. Attenuation of and protection induced by a leucine auxotroph of *Mycobacterium tuberculosis*. *Infection and Immunity*. 2000;68(5):2888-98.
- [79] Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model [In Process Citation]. *ProcNatlAcadSciUSA*. 2000;97(25):13853-8.

- [80] Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, Collins FM, et al. A pantothenate auxotroph of *Mycobacterium tuberculosis* is highly attenuated and protects mice against tuberculosis. *NatMed*. 2002;8(10):1171-4.
- [81] Waddell RD, Chintu C, Lein AD, Zumla A, Karagas MR, Baboo KS, et al. Safety and immunogenicity of a five-dose series of inactivated *Mycobacterium vaccae* vaccination for the prevention of HIV-associated tuberculosis. *Clinical Infectious Diseases*. 2000;30 Suppl 3:S309-15.:S309-S15.
- [82] Feng CG, Blanchard TJ, Smith GL, Hill AV, Britton WJ. Induction of CD8+ T-lymphocyte responses to a secreted antigen of *Mycobacterium tuberculosis* by an attenuated vaccinia virus. *Immunology and Cell Biology*. 2001;79(6):569-75.
- [83] Hess J, Grode L, Hellwig J, Conradt P, Gentschev I, Goebel W, et al. Protection against murine tuberculosis by an attenuated recombinant *Salmonella typhimurium* vaccine strain that secretes the 30-kDa antigen of *Mycobacterium bovis* BCG 2472. *FEMS Immunology and Medical Microbiology*. 2000;27(4):283-9.
- [84] Malin AS, Huygen K, Content J, Mackett M, Brandt L, Andersen P, et al. Vaccinia expression of mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of *M. tuberculosis* Ag85 [In Process Citation]. *MicrobesInfect*. 2000;2(14):1677-85.
- [85] McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. *Infection and Immunity*. 2001;69(2):681-6.
- [86] Mollenkopf HJ, Groine-Triebkorn D, Andersen P, Hess J, Kaufmann SH. Protective efficacy against tuberculosis of ESAT-6 secreted by a live *Salmonella typhimurium* vaccine carrier strain and expressed by naked DNA. *Vaccine*. 2001;19(28-29):4028-35.
- [87] Zhu X, Venkataprasad N, Ivanyi J, Vordermeier HM. Vaccination with recombinant vaccinia viruses protects mice against *Mycobacterium tuberculosis* infection 114. *Immunology*. 1997;92(1):6-9.
- [88] Bretscher P, Menon J, Power C, Uzonna J, Wei G. A case for a neonatal, low-dose BCG vaccination trial. *ScandJ InfectDis*. 2001;33(4):253-7.
- [89] Bretscher PA. Prospects for low dose BCG vaccination against tuberculosis 248. *Immunobiology*. 1994;191(4-5):548-54.
- [90] Power CA, Wei G, Bretscher PA. Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. *Infection and Immunity*. 1998;66(12):5743-50.
- [91] Hoft DF, Brown RM, Belshe RB. Mucosal bacille calmette-Guerin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses. *Clinical Infectious Diseases*. 2000;30 Suppl 3:S217-22.:S217-S22.
- [92] Brooks JV, Frank AA, Keen MA, Bellisle JT, Orme IM. Boosting vaccine for tuberculosis. *Infection and Immunity*. 2001;69(4):2714-7.
- [93] Griffin JF, Chinn DN, Rodgers CR, Mackintosh CG. Optimal models to evaluate the protective efficacy of tuberculosis vaccines. *Tuberculosis(Edinb)*. 2001;81(1-2):133-9.

- [94] Griffin JF, Mackintosh CG, Slobbe L, Thomson AJ, Buchan GS. Vaccine protocols to optimise the protective efficacy of BCG. *Tubercle and Lung Disease*. 1999;79(3):135-43.
- [95] McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AV. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. *Infection and Immunity*. 2002;70(3):1623-6.
- [96] Reed SG, Alderson MR, Dalemans W, Lobet Y, Skeiky YAW. Prospects For a Better Vaccine Against Tuberculosis. *Tuberculosis(Edinb)*. 2003;83(1-3):213-9.
- [97] Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. *The Journal of infectious diseases*. 2008;198(10):1491-501. PMID: 2670060.
- [98] Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. *The Journal of clinical investigation*. 2005;115(9):2472-9. PMID: 1187936.
- [99] McShane H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. *Philosophical transactions of the Royal Society of London Series B, Biological sciences*. 2011;366(1579):2782-9. PMID: 3146779.
- [100] Mackaness GB. The Immunological Basis of Acquired Cellular Resistance. *The Journal of experimental medicine*. 1964;120:105-20. PMID: 2137723.
- [101] Mackaness GB. Resistance to intracellular infection. *The Journal of infectious diseases*. 1971;123(4):439-45.
- [102] Orme IM. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. *Journal of Immunology*. 1987;138(1):293-8.
- [103] Orme IM. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. *Infection and Immunity*. 1988;56(12):3310-2.
- [104] Orme IM. Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection. *Journal of Immunology*. 1988;140(10):3589-93.
- [105] Orme IM. Development of new vaccines and drugs for TB: limitations and potential strategic errors. *Future microbiology*. 2011;6(2):161-77. PMID: 3122326.
- [106] Orme IM, Collins FM. Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients. *Journal of Experimental Medicine*. 1983;158(1):74-83.
- [107] Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *Journal of immunology*. 1986;136(7):2348-57.
- [108] Sallusto F, Langenkamp A, Geginat J, Lanzavecchia A. Functional subsets of memory T cells identified by CCR7 expression. *Current topics in microbiology and immunology*. 2000;251:167-71.

- [109] Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature*. 1999;401(6754):708-12.
- [110] Russell DG. Who puts the tubercle in tuberculosis? *Nature reviews*. 2007;5(1):39-47.
- [111] Noss EH, Harding CV, Boom WH. *Mycobacterium tuberculosis* inhibits MHC class II antigen processing in murine bone marrow macrophages. *Cell Immunol*. 2000;201(1):63-74.
- [112] Deretic V. Autophagy as an immune defense mechanism. *Curr Opin Immunol*. 2006;18(4):375-82.
- [113] Hirsch CS, Johnson JL, Ellner JJ. Pulmonary tuberculosis. *Curr Opin Pulm Med*. 1999;5(3):143-50.
- [114] Rojas RE, Balaji KN, Subramanian A, Boom WH. Regulation of human CD4(+) alphabeta T-cell-receptor-positive (TCR(+)) and gammadelta TCR(+) T-cell responses to *Mycobacterium tuberculosis* by interleukin-10 and transforming growth factor beta. *Infection and Immunity*. 1999;67(12):6461-72.
- [115] Turner J, Gonzalez-Juarrero M, Ellis DL, Basaraba RJ, Kipnis A, Orme IM, et al. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. *J Immunol*. 2002;169(11):6343-51.
- [116] Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM. Eicosanoid pathways regulate adaptive immunity to *Mycobacterium tuberculosis*. *Nature immunology*. 2010;11(8):751-8.
- [117] van der Wel N, Hava D, Houben D, Fluitsma D, van Zon M, Pierson J, et al. *M. tuberculosis* and *M. leprae* translocate from the phagolysosome to the cytosol in myeloid cells. *Cell*. 2007;129(7):1287-98.
- [118] Bold TD, Banaei N, Wolf AJ, Ernst JD. Suboptimal activation of antigen-specific CD4+ effector cells enables persistence of *M. tuberculosis* in vivo. *PLoS pathogens*. 2011;7(5):e1002063. PMID: 3102708.
- [119] Flynn JL. Lessons from experimental *Mycobacterium tuberculosis* infections. *Microbes and infection / Institut Pasteur*. 2006;8(4):1179-88.
- [120] Ulrichs T, Kaufmann SH. New insights into the function of granulomas in human tuberculosis. *J Pathol*. 2006;208(2):261-9.
- [121] Day TA, Koch M, Nouailles G, Jacobsen M, Kosmiadi GA, Miekley D, et al. Secondary lymphoid organs are dispensable for the development of T-cell-mediated immunity during tuberculosis. *Eur J Immunol*. 2010;40(6):1663-73.
- [122] Appelberg R. Protective role of interferon gamma, tumor necrosis factor alpha and interleukin-6 in *Mycobacterium tuberculosis* and *M. avium* infections. *Immunobiology*. 1994;191(4-5):520-5.
- [123] Appelberg R, Castro AG, Pedrosa J, Silva RA, Orme IM, Minoprio P. Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of *Mycobacterium avium* infection. *Infection and Immunity*. 1994;62(9):3962-71.
- [124] Chackerian AA, Perera TV, Behar SM. Gamma interferon-producing CD4+ T lymphocytes in the lung correlate with resistance to infection with *Mycobacterium tuberculosis*. *Infection and Immunity*. 2001;69(4):2666-74.


- [125] Flesch I, Kaufmann SH. Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis 1356. *Journal of Immunology*. 1987;138(12):4408-13.
- [126] Flynn JL. Why is IFN-gamma insufficient to control tuberculosis? [letter] 2328. *Trends Microbiol*. 1999;7(12):477-8.
- [127] Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection 1422. *Journal of Experimental Medicine*. 1993;178(6):2249-54.
- [128] Kaufmann SH. Role of T-cell subsets in bacterial infections 2500. *Current Opinion In Immunology*. 1991;3(4):465-70.
- [129] Kawamura I, Tsukada H, Yoshikawa H, Fujita M, Nomoto K, Mitsuyama M. IFN-gamma-producing ability as a possible marker for the protective T cells against Mycobacterium bovis BCG in mice. *J Immunol*. 1992;148(9):2887-93.
- [130] Sugawara I, Yamada H, Kazumi Y, Doi N, Otomo K, Aoki T, et al. Induction of granulomas in interferon-gamma gene-disrupted mice by avirulent but not by virulent strains of Mycobacterium tuberculosis. *J MedMicrobiol*. 1998;47(10):871-7.
- [131] Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. *The Journal of experimental medicine*. 1993;178(6):2243-7. PMID: 2191280.
- [132] Andersen P, Smedegaard B. CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. *Infect Immun*. 2000;68(2):621-9. PMID: 97184.
- [133] Bloom BR, Flynn J, McDonough K, Kress Y, Chan J. Experimental approaches to mechanisms of protection and pathogenesis in M. tuberculosis infection. *Immunobiology*. 1994;191(4-5):526-36.
- [134] Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, Flynn JL. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. *Journal of Immunology*. 1999;162(9):5407-16.
- [135] Ladel CH, Blum C, Dreher A, Reifenberg K, Kaufmann SH. Protective role of gamma/delta T cells and alpha/beta T cells in tuberculosis [published erratum appears in *Eur J Immunol* 1995 Dec;25(12):3525]. *European Journal of Immunology*. 1995;25(10):2877-81.
- [136] Ladel CH, Daugelat S, Kaufmann SH. Immune response to Mycobacterium bovis bacille Calmette Guerin infection in major histocompatibility complex cla. *European Journal of Immunology*. 1995;25(2):377-84.
- [137] Ladel CH, Szalay G, Riedel D, Kaufmann SH. Interleukin-12 secretion by Mycobacterium tuberculosis-infected macrophages. *Infection and Immunity*. 1997;65(5):1936-8.
- [138] Leveton C, Barnass S, Champion B, Lucas S, De Souza B, Nicol M, et al. T-cell-mediated protection of mice against virulent Mycobacterium tuberculosis. *Infect Immun*. 1989;57(2):390-5. PMID: 313109.
- [139] Munk ME, Gatrill AJ, Kaufmann SH. Target cell lysis and IL-2 secretion by gamma/delta T lymphocytes after activation with bacteria. *Journal of Immunology*. 1990;145(8):2434-9.

- [140] Stenger S, Mazzaccaro RJ, Uyemura K, Cho S, Barnes PF, Rosat JP, et al. Differential effects of cytolytic T cell subsets on intracellular infection. *Science*. 1997;276(5319):1684-7.
- [141] Tascon RE, Stavropoulos E, Lukacs KV, Colston MJ. Protection against *Mycobacterium tuberculosis* infection by CD8+ T cells requires the production of gamma interferon. *Infection and Immunity*. 1998;66(2):830-4.
- [142] Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, Flynn JL. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis 14. *Journal of Immunology*. 1999;162(9):5407-16.
- [143] Serbina NV, Flynn JL. Early emergence of CD8(+) T cells primed for production of type 1 cytokines in the lungs of *Mycobacterium tuberculosis*-infected mice 1413. *Infection and Immunity*. 1999;67(8):3980-8.
- [144] Scanga CA, Mohan VP, Yu K, Joseph H, Tanaka K, Chan J, et al. Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2. *Journal of Experimental Medicine*. 2000;192(3):347-58.
- [145] Orme IM. Characteristics and specificity of acquired immunologic memory to *Mycobacterium tuberculosis* infection 406. *Journal of Immunology*. 1988;140(10):3589-93.
- [146] Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice 1389. *Journal of Experimental Medicine*. 1993;178(6):2243-7.
- [147] Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection 1537. *New England Journal of Medicine*. 1996;335(26):1941-9.
- [148] Hirsch CS, Toossi Z, Othieno C, Johnson JL, Schwander SK, Robertson S, et al. Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. *Journal of Infectious Diseases*. 1999;180(6):2069-73.
- [149] Zhang M, Lin Y, Iyer DV, Gong J, Abrams JS, Barnes PF. T-cell cytokine responses in human infection with *Mycobacterium tuberculosis* 1481. *Infection and Immunity*. 1995;63(8):3231-4.
- [150] Bold TD, Banaei N, Wolf AJ, Ernst JD. Suboptimal activation of antigen-specific CD4+ effector cells enables persistence of *M. tuberculosis* in vivo. *PLoS pathogens*. 2011;7(5):e1002063. PMID: 3102708.
- [151] Bean AG, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol *Mycobacterium tuberculosis* infection, which is not compensated for by lymphotoxin. *J Immunol*. 1999;162(6):3504-11.
- [152] Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, et al. Tumor necrosis factor-alpha is required in the protective immune response against *Mycobacterium tuberculosis* in mice 221. *Immunity*. 1995;2(6):561-72.
- [153] Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *New England Journal of Medicine*. 2001;345(15):1098-104.

- [154] Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cillely GE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. *Nature immunology*. 2007;8(4):369-77.
- [155] Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, Jelley-Gibbs DM, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. *J Immunol*. 2005;175(2):788-95.
- [156] Muller I, Cobbold SP, Waldmann H, Kaufmann SH. Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells 1355. *Infection and Immunity*. 1987;55(9):2037-41.
- [157] Orme IM. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. *J Immunol*. 1987;138(1):293-8.
- [158] Silva CL, Silva MF, Pietro RC, Lowrie DB. Protection against tuberculosis by passive transfer with T-cell clones recognizing mycobacterial heat-shock protein 65 1628. *Immunology*. 1994;83(3):341-6.
- [159] Winau F, Hegasy G, Kaufmann SH, Schaible UE. No life without death--apoptosis as prerequisite for T cell activation. *Apoptosis*. 2005;10(4):707-15.
- [160] Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection 302. *ProcNatAcadSciUSA*. 1992;89(24):12013-7.
- [161] Ladel CH, Daugelat S, Kaufmann SH. Immune response to Mycobacterium bovis bacille Calmette Guerin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. *Eur J Immunol*. 1995;25(2):377-84.
- [162] Behar SM, Dascher CC, Grusby MJ, Wang CR, Brenner MB. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis 1000. *Journal of Experimental Medicine*. 1999;189(12):1973-80.
- [163] Rolph MS, Raupach B, Kobernick HH, Collins HL, Perarnau B, Lemonnier FA, et al. MHC class Ia-restricted T cells partially account for beta2-microglobulin-dependent resistance to Mycobacterium tuberculosis. *Eur J Immunol*. 2001;31(6):1944-9.
- [164] Lalvani A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P, et al. Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis 1052. *ProcNatAcadSciUSA*. 1998;95(1):270-5.
- [165] Lewinsohn DM, Briden AL, Reed SG, Grabstein KH, Alderson MR. Mycobacterium tuberculosis-reactive CD8+ T lymphocytes: the relative contribution of classical versus nonclassical HLA restriction 2419. *Journal of Immunology*. 2000;165(2):925-30.
- [166] Lewinsohn DM, Zhu L, Madison VJ, Dillon DC, Fling SP, Reed SG, et al. Classically restricted human CD8(+) T lymphocytes derived from mycobacterium tuberculosis-infected cells: definition of antigenic specificity [In Process Citation] 2420. *Journal of Immunology*. 2001;166(1):439-46.
- [167] Mohaghehpour N, Gammon D, Kawamura LM, van Vollenhoven A, Benike CJ, Engleman EG. CTL response to Mycobacterium tuberculosis: identification of an

- immunogenic epitope in the 19-kDa lipoprotein 61. *Journal of Immunology*. 1998;161(5):2400-6.
- [168] Tan JS, Canaday DH, Boom WH, Balaji KN, Schwander SK, Rich EA. Human alveolar T lymphocyte responses to *Mycobacterium tuberculosis* antigens: role for CD4+ and CD8+ cytotoxic T cells and relative resistance of alveolar macrophages to lysis 1604. *Journal of Immunology*. 1997;159(1):290-7.
- [169] Turner J, Dockrell HM. Stimulation of human peripheral blood mononuclear cells with live *Mycobacterium bovis* BCG activates cytolytic CD8+ T cells in vitro 184. *Immunology*. 1996;87(3):339-42.
- [170] Heinzel AS, Grotzke JE, Lines RA, Lewinsohn DA, McNabb AL, Streblov DN, et al. HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells. *Journal of Experimental Medicine*. 2002;196(11):1473-81.
- [171] Lewinsohn DM, Alderson MR, Briden AL, Riddell SR, Reed SG, Grabstein KH. Characterization of human CD8+ T cells reactive with *Mycobacterium tuberculosis*-infected antigen-presenting cells 1781. *Journal of Experimental Medicine*. 1998;187(10):1633-40.
- [172] Moody DB, Reinhold BB, Reinhold VN, Besra GS, Porcelli SA. Uptake and processing of glycosylated mycolates for presentation to CD1b-restricted T cells 1772. *Immunology Letters*. 1999;65(1-2):85-91.
- [173] Rosat JP, Grant EP, Beckman EM, Dascher CC, Sieling PA, Frederique D, et al. CD1-restricted microbial lipid antigen-specific recognition found in the CD8+ alpha beta T cell pool 1725. *Journal of Immunology*. 1999;162(1):366-71.
- [174] Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, et al. Identification of human T cell antigens for the development of vaccines against *Mycobacterium tuberculosis*. *J Immunol*. 2008;181(11):7948-57. PMID: 2586986.
- [175] Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, Raman VS, et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. *PLoS one*. 2010;5(10):e13677. PMID: 2965144.
- [176] Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, et al. Development of Glucopyranosyl Lipid A, a Synthetic TLR4 Agonist, as a Vaccine Adjuvant. *PLoS one*. 2011;6(1):e16333.
- [177] Von Eschen K, Morrison R, Braun M, Ofori-Anyinam O, De Kock E, Pavithran P, et al. The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. *Human vaccines*. 2009;5(7):475-82.
- [178] Rowland R, McShane H. Tuberculosis vaccines in clinical trials. *Expert review of vaccines*. 2011;10(5):645-58.
- [179] Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, Turner OC, et al. The protective effect of the *Mycobacterium bovis* BCG vaccine is increased by coadministration with the *Mycobacterium tuberculosis* 72-kilodalton fusion polyprotein Mtb72F in *M. tuberculosis*-infected guinea pigs. *Infect Immun*. 2004;72(11):6622-32.
- [180] Reed SG, Coler RN, Dalemans W, Tan EV, DeLa Cruz EC, Basaraba RJ, et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(7):2301-6. PMID: 2650151.

- [181] Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. *J Immunol.* 2004;172(12):7618-28.
- [182] Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, Aagaard C, et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. *PloS one.* 2008;3(9):e3116. PMID: 2525815.
- [183] Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y, et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from *M. tuberculosis* (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. *Biochim Biophys Acta.* 2005;1718(1-2):22-31.
- [184] Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. *Infect Immun.* 2004;72(3):1608-17. PMID: 356055.
- [185] Agger EM, Rosenkrands I, Olsen AW, Hatch G, Williams A, Kritsch C, et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. *Vaccine.* 2006;24(26):5452-60.
- [186] Kamath AT, Rochat AF, Christensen D, Agger EM, Andersen P, Lambert PH, et al. A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells. *PloS one.* 2009;4(6):e5771. PMID: 2685976.
- [187] Kamath AT, Rochat AF, Valenti MP, Agger EM, Lingnau K, Andersen P, et al. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. *PloS one.* 2008;3(11):e3683. PMID: 2577009.
- [188] Langermans JA, Doherty TM, Vervenne RA, van der Laan T, Lyashchenko K, Greenwald R, et al. Protection of macaques against *Mycobacterium tuberculosis* infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. *Vaccine.* 2005;23(21):2740-50.
- [189] Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. *Infect Immun.* 2004;72(10):6148-50. PMID: 517547.
- [190] Brock I, Weldingh K, Leyten EM, Arend SM, Ravn P, Andersen P. Specific T-cell epitopes for immunoassay-based diagnosis of *Mycobacterium tuberculosis* infection. *J Clin Microbiol.* 2004;42(6):2379-87. PMID: 427833.
- [191] Aagaard C, Hoang TT, Izzo A, Billeskov R, Troudt J, Arnett K, et al. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against *Mycobacterium tuberculosis* is highly dependent on the antigen dose. *PloS one.* 2009;4(6):e5930. PMID: 2691953.
- [192] Skeiky YA, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, Goetz MA, et al. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. *Vaccine.* 2010;28(4):1084-93.



Understanding Tuberculosis - Analyzing the Origin of Mycobacterium Tuberculosis Pathogenicity

Edited by Dr. Pere-Joan Cardona

ISBN 978-953-307-942-4

Hard cover, 560 pages

Publisher InTech

Published online 24, February, 2012

Published in print edition February, 2012

Mycobacterium tuberculosis in an attempt to understand the extent to which the bacilli has adapted itself to the host and to its final target. On the other hand, there is a section in which other specialists discuss how to manipulate this immune response to obtain innovative prophylactic and therapeutic approaches to truncate the intimal co-evolution between Mycobacterium tuberculosis and the Homo sapiens.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Rhea N. Coler, Susan L. Baldwin, and Steven G. Reed (2012). Vaccines Against Mycobacterium tuberculosis: An Overview from Preclinical Animal Studies to the Clinic, Understanding Tuberculosis - Analyzing the Origin of Mycobacterium Tuberculosis Pathogenicity, Dr. Pere-Joan Cardona (Ed.), ISBN: 978-953-307-942-4, InTech, Available from: <http://www.intechopen.com/books/understanding-tuberculosis-analyzing-the-origin-of-mycobacterium-tuberculosis-pathogenicity/vaccines-against-mycobacterium-tuberculosis-an-overview-from-preclinical-animal-studies-to-the-clini>

INTECH

open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.